This early and basic study suggests that the evaluation of inflammatory markers, including IL-6, and quantification of CD8+ T-lymphocytes and their subpopulations can be used to follow-up patients with lung adenocarcinoma. The gene discussed is CD8A; the disease is lung adenocarcinoma.